Home > About > Faculty Profiles > Y. Hwan Kim, Ph.D.

Y. Hwan Kim, Ph.D.



Campus Address: Science Center North 166/168

Emailyhkim [at] desu.edu



  • B.S., Plant Physiology/Genetic Engineering, Korea University, Seoul, S. Korea, 1996
  • M.S., Biotechnology, Korea University, 1998
  • Ph.D., Neuroscience, UCLA, 2005
  • Post-doctoral training, Parkinson’s disease, Johns Hopkins Medical School, 2007
  • Post-doctoral training, Parkinson’s disease, Buck Institute for Aging Research, 2012

Research Interests

Parkinson’s disease (PD) therapeutic target validation; cellular senescence in PD pathology; deSUMOylation as a therapeutic intervention for PD; and NADPH oxidase inhibition as a therapeutic application for PD.

Research Expertise

  • Neuroscience
  • Imaging
  • Mentoring
  • Data Analytics
  • Project Management
  • Grant Writing

Industry/Consulting Experience

  • AptaBio Therapeutics, Developing novel NOX inhibitors as potential therapeutics in Parkinson’s disease. February 2019 - January 2025
  • AurimMed Pharma, Screening novel compounds from AurimMed Pharma for developing Parkinson’s disease therapeutics. February 2014 - December 2019

Selected Publications

  • Ofori K, Ghosh A, Verma DK, Wheeler DB, Cabrera G, Seo JB and Kim YH. A novel NOX inhibitor alleviates Parkinson’s disease pathology in PFF-injected mice. Int J Mol Sci. 2023 Sep 19;24(18):14278. PMID: 37762579

  • Chae KS, Oh IT, Jeong SH, Kim YH, Kim SC and Kim YK. Geomagnetic field influences probabilistic abstract decision-making in humans. arXiv. 2023 Jun (2306):16292. https://doi.org/10.48550/arXiv.2306.16292

  • Martinez A†, Hernandez-Quijada K†, Ghosh A†, Cabrera G, Scott D, Aikins A, Kwon I and Kim YH. The combination of Violet light and Infra-Red or Violet light only suppresses the survival of regular and multiple-drug resistant bacterial strains. J. Photochem & Photobiol. 2023 Apr (14),100167. doi.org/10.1016/j.jpap.2023.100167

  • Ghosh A, Verma DK, Cabrera G, Ofori K, Hernandez-Quijada K, Kim JK, Chung JH, Moore M, Moon SH, Seo JB and Kim YH. A novel NOX inhibitor treatment attenuates Parkinson’s disease related pathology in mouse models. Int J. Mol Sci. 2022 Apr 12; 23(8), 4262. PMID: 35457082

  • Verma DK, Seo BA, Ghosh A, Ma SX, Hernandez-Quijada K, Andersen JK, Ko HS and Kim YH. Alpha-synuclein preformed fibrils induce cellular senescence in Parkinson’s disease models. Cells. 2021 Jul 5; 10(7):1694. PMID: 34359864

  • Verma DK, Ghosh A, Ruggiero L, Cartier E, Janezic EM, Williams D, Jung EJ, Moore M, Seo JB, and Kim YH. The SUMO conjugase Ubc9 protects Dopaminergic cells from cytotoxicity and enhances the stability of α-synuclein in Parkinson’s disease models. eNeuro. 2020 Sept 23, 0134-20. PMID: 32887693

  • Cartier E, Garcia-Olivares J, Lin ML, Janezic EM, Viana J, Moore M, Torres G, and Kim YH. The SUMO conjugase Ubc9 prevents the degradation of dopamine transporter, enhancing its cell surface level and dopamine uptake. Frontiers in Cellular Neuroscience. 2019 Feb 09, 13(35):1-23. PMID: 30828290

  • Janezic EM, Caviness JE, Kanda SG, Davis XD, and Kim YH. Commercially available pesticides cause additive or synergistic damages in dopaminergic cells: Relevance for Parkinson’s disease pathology. Annals of Neurodegenerative disorders. 2016 1(2):1010:1-9.

  • Lazzara CL and Kim YH. Potential application of Lithium in Parkinson’s and other neurodegenerative diseases. Frontiers in Neuroscience. 2015 Oct 27:9:403. review. PMID: 26578864

  • Lazzara CL, Riley RR, Rane A, Andersen JK, and Kim YH. The combination of lithium and L-dopa/Carbidopa reduces abnormal involuntary movements (AIMs) in MPTP-lesioned mice: relevance for Parkinson’s disease Therapy. Brain Res. 2015 Jul, 1622:127-136. PMID: 26119916


  • NIH, 1R15NS121784 (PI), 12/01/21 - 11/30/24, 300K (Direct), Prevention of alpha-synuclein deSUMOylation as a Parkinson’s therapeutic target.

  • NIH, P20GM139760 (Project lead), 02/01/23 - 01/31/25 (NCE), Direct: 188k, Senolytics and Exercise Alleviate Aging-Related Parkinson’s and Bone Diseases.

  • NIH, 5T32GM144895 (m-PI), 05/01/22 - 4/30/27, Direct: 1.9M, Diversifying Neuroscience through predoctoral training at Delaware State University.

  • Private fund from AptaBio, PI, 2/01/19 - 01/31/25, Developing novel NOX inhibitors as potential therapeutics in Parkinson’s disease.